Kimberly-ClarkAmbev

Kimberly-Clark vs Ambev

Global maker of household and personal care products vs Leading Latin American brewer and beverage producer. Which is the better buy for your portfolio in November 2026? Plain-English answer below.

Kimberly-Clark sells the tissue and personal care staples that consumers grab regardless of economic conditions while Ambev dominates beer and soft drink sales across Latin America. Both are consumer ...

Why It’s Moving

Kimberly-Clark

Kimberly-Clark Beats Earnings Estimates as Kenvue Integration and Cost Synergies Drive Profit Growth

  • Q3 net income rose sharply, beating estimates primarily due to lower interest costs, even though organic sales declined amid pricing pressures and false quality claims affecting diaper sales in China.
  • The company officially completed the acquisition of Kenvue, creating a global consumer health leader with 10 billion-dollar brands and reiterating targets for approximately $2.1 billion in run-rate synergies.
  • Management maintained its full-year adjusted EPS guidance, signaling confidence in the integration pipeline and defensive cash generation capabilities despite softer top-line performance.
Sentiment:
🐃Bullish
Ambev

Ambev Q3 Results Spark Debate as Analysts Split on Valuation and Growth Outlook

  • Q3 net revenue missed expectations for some analysts due to year-over-year volume declines and gross margin pressure from rising costs, leading to a downgrade to 'hold' citing limited upside versus sector peers.
  • Conversely, bullish perspectives emphasize significant pricing power, robust free cash flow, and margin improvements despite cost headwinds, viewing post-election volatility as a compelling entry point.
  • Strategic initiatives such as digital expansion via BEES and Zé Delivery are credited with enhancing margin protection and tapping into younger, high-margin consumer segments.
Sentiment:
🌋Volatile

Investment Analysis

Pros

  • Kimberly-Clark continues to deliver low single-digit growth in adjusted operating profit and organic sales, indicating steady underlying business performance despite recent headwinds.
  • A recently announced $48.7 billion acquisition of Kenvue, owner of Tylenol, could enhance scale, diversify revenue, and strengthen the portfolio in consumer health segments.
  • The company’s share price, having declined significantly over the past year, is trading at a notable discount to analyst price targets and intrinsic value estimates.

Considerations

  • Divestitures such as the exit from the PPE segment and US private-label diaper business will negatively impact reported sales and operating profit growth for the full year.
  • Currency translation and higher net interest expense are forecast to weigh on both operating profit and adjusted earnings per share growth in the near term.
  • Increased competition and innovation pressure in consumer staples may challenge Kimberly-Clark’s ability to maintain market share and margins going forward.
Ambev

Ambev

ABEV

Pros

  • Ambev benefits from a dominant market position in Brazil and a growing footprint across Latin America, providing resilience through economic cycles and demographic trends.
  • The company has a track record of strong cash flow generation, enabling steady investments in marketing, distribution, and premium product launches to drive growth.
  • Ambev’s exposure to fast-growing beer and non-alcoholic beverage segments in Latin America supports long-term revenue expansion potential.

Considerations

  • Volatile currency movements across Latin America, especially the Brazilian real, can materially impact reported financial results and dividend payouts to shareholders.
  • Regulatory risks, including taxation and advertising restrictions on alcohol, remain a persistent challenge in key markets such as Brazil and Argentina.
  • Intensifying competition from both global brewers and local craft brands may pressure Ambev’s pricing power and volume growth in core categories.

Kimberly-Clark (KMB) Next Earnings Date

Kimberly-Clark Corporation has a confirmed upcoming earnings date scheduled for November 5, 2026. This report will cover the company's third-quarter fiscal results. The specific time of day for this release is currently listed as To Be Determined.

Ambev (ABEV) Next Earnings Date

Ambev S.A. (NYSE: ABEV) is scheduled to release its next earnings report on October 29, 2026. The report will cover the third quarter of fiscal 2026. This date is consistent with the company’s typical late-October reporting schedule.

Buy KMB or ABEV in Nemo

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Frequently asked questions